Calcitonin gene-related peptide monoclonal antibody: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) (create) |
Notjusttired (talk | contribs) (expand, refs) |
||
| Line 1: | Line 1: | ||
{{stub}} | {{stub}} | ||
'''Calcitonin gene-related peptide monoclonal antibodies''' (mAbs) or '''CGRP mAbs''' are a new type of preventative [[migraine]] treatment.<ref name="migrainetrust">https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/</ref><ref name="drugscom"/> | '''Calcitonin gene-related peptide monoclonal antibodies''' (mAbs) or '''CGRP mAbs''' are a new type of preventative [[migraine]] treatment.<ref name="migrainetrust">{{Cite web|url=https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/|title=Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies|website=The Migraine Trust|language=en-US|access-date=2021-10-12}}</ref><ref name="drugscom" /> CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines. | ||
Unlike known the small molecule CGRP antagonists known as [[:Category:Gepants|gepants]], CGRP mAbs are used for preventation rather than treatment of an existing migraine.<ref name="drugscom">https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/</ref><ref name="gepants">https://pubmed.ncbi.nlm.nih.gov/31081399/</ref> | Unlike known the small molecule CGRP antagonists known as [[:Category:Gepants|gepants]], CGRP mAbs are used for preventation rather than treatment of an existing migraine.<ref name="drugscom">{{Cite web|url=https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/|title=What are the new drugs for the treatment of migraines?|website=Drugs.com|language=en|access-date=2021-10-12}}</ref><ref name="gepants">{{Cite journal|last=Negro|first=Andrea|author-link=|last2=Martelletti|first2=Paolo|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Jun 2019|title=Gepants for the treatment of migraine|url=https://pubmed.ncbi.nlm.nih.gov/31081399/|journal=Expert Opinion on Investigational Drugs|volume=28|issue=6|pages=555–567|doi=10.1080/13543784.2019.1618830|issn=1744-7658|pmc=|pmid=31081399|access-date=|quote=|via=}}</ref> | ||
==Drugs== | ==Drugs== | ||
| Line 10: | Line 10: | ||
*Fremanezumab (Ajovy), approved in 2018 | *Fremanezumab (Ajovy), approved in 2018 | ||
*Galcanezumab (Emgality), approved in 2018<ref name="drugscom" /> | *Galcanezumab (Emgality), approved in 2018<ref name="drugscom" /> | ||
== Uses == | |||
A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve [[pain]] in patients who also had migraines.<ref>{{Cite journal|last=Kang|first=Seung Ah|last2=Govindarajan|first2=Raghav|date=2021|title=Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27153|journal=Muscle & Nerve|language=en|volume=63|issue=4|pages=563–567|doi=10.1002/mus.27153|issn=1097-4598}}</ref> | |||
==News and articles == | ==News and articles == | ||
| Line 16: | Line 19: | ||
==Learn more == | ==Learn more == | ||
*[https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ Calcitonin gene-related peptide monoclonal antibodies] - The Migraine Trust | *[https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ Calcitonin gene-related peptide monoclonal antibodies] - The Migraine Trust | ||
*[https://www.migraine.org.au/cgrp CGRP Medications] - Migraine Australia | |||
==See also == | ==See also == | ||
Revision as of 00:59, October 12, 2021
 | This article is a stub. |
Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.[1][2] CGRP mAbs block the release of calcitonin gene-related peptide, a neurotransmitter known to cause migraines.
Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.[2][3]
Drugs[edit | edit source]
Currently FDA-licensed CGRP mAbs are:
- Eptinezumab (Vyepti), approved in 2020
- Erenumab (Aimovig), approved in 2018
- Fremanezumab (Ajovy), approved in 2018
- Galcanezumab (Emgality), approved in 2018[2]
Uses[edit | edit source]
A small retrospective chart review by Kang and Govindarajan (2020) found that CGRP mAbs also significantly decreased peripheral nerve pain in patients who also had migraines.[4]
News and articles[edit | edit source]
- 2020, Can migraines be untangled by new medical thinking? - The Observer
Learn more[edit | edit source]
- Calcitonin gene-related peptide monoclonal antibodies - The Migraine Trust
- CGRP Medications - Migraine Australia
See also[edit | edit source]
References[edit | edit source]
- ↑ "Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies". The Migraine Trust. Retrieved October 12, 2021.
- ↑ 2.0 2.1 2.2 "What are the new drugs for the treatment of migraines?". Drugs.com. Retrieved October 12, 2021.
- ↑ Negro, Andrea; Martelletti, Paolo (June 2019). "Gepants for the treatment of migraine". Expert Opinion on Investigational Drugs. 28 (6): 555–567. doi:10.1080/13543784.2019.1618830. ISSN 1744-7658. PMID 31081399.
- ↑ Kang, Seung Ah; Govindarajan, Raghav (2021). "Anti-calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache". Muscle & Nerve. 63 (4): 563–567. doi:10.1002/mus.27153. ISSN 1097-4598.
